Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker October 17, 2019
Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder October 7, 2019
